AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
+5
Published on July 23
AstraZeneca's $50 billion commitment is just the beginning. This massive investment could trigger a wave of similar moves by other pharmaceutical giants, creating sustained demand for the companies that build and equip these facilities.
U.S. tariff policies and supply chain security concerns are driving this reshoring trend. These aren't temporary market shifts but strategic moves backed by government support and long-term industrial policy.
While everyone focuses on the drug makers, the real opportunity might be in the picks and shovels. These companies provide the essential tools, equipment, and services that make pharmaceutical manufacturing possible.
AstraZeneca's massive $50 billion U.S. investment signals a major shift toward domestic pharmaceutical manufacturing. This trend, driven by tariff policies and supply chain resilience needs, creates a ripple effect across the entire biopharmaceutical ecosystem. We see this as a transformative moment that will benefit companies throughout the value chain.
This group focuses on the enablers of pharmaceutical reshoring rather than just the drug makers themselves. These companies build facilities, manufacture specialized equipment, and supply critical materials needed for domestic biopharmaceutical production. It's a play on the infrastructure and tools required for this industrial shift.
Each company was selected for its direct role in supporting pharmaceutical manufacturing expansion. From life sciences equipment makers to facility builders and raw material suppliers, these stocks are positioned to capture demand from large-scale capital projects as the industry builds out domestic capacity.
Market capitalisation breakdown for the basket 'Pharma's American Reshoring Wave'.
TMO: $210.70B
RGEN: $8.82B
AVTR: $10.64B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+43.40%
On average, analysts expect assets in this group to grow 43.4% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
